Robin Shane Readnour, Director at AN2 Therapeutics, Inc. (ANTX), sold 3,669 shares at $21.93 ($80K) on 2024-01-10, disclosed to the SEC on 2024-01-12.
Scheduled sale ($80k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.92 | 1,800 | $39K | 49.0% |
| 2 | $21.93 | 1,869 | $41K | 51.0% |
| Total | $21.93 avg | 3,669 | $80K | 100% |
| Filing → |
| ANTX | SELL | 2026-08-19 | $213K | — | Filing → |
| ANTX | BUY | 2024-12-10 | $79K | — | Filing → |
| ANTX | BUY | 2024-11-27 | $53K | — | Filing → |